



Meeting: Trust Board Meeting in Public

### **27 November 2024**

Agenda item	Private Board Summary Report
Board Lead	Chief Executive Officer
Type name of Author	Senior Trust Board Administrator
Attachments	None
Purpose	Information
Previously considered	n/a

# **Executive Summary**

The purpose of this report is to provide a summary of matters discussed at the Board meeting held in private on 30 October 2024.

The matters considered at this session of the Board were as follows:

- Independence of Charity
- Microbiology Business Case
- Place Integration
- Urgent & Emergency Care Contract
- System Recovery Transformation Board

Decision	The Board	The Board is requested to note the contents of the report.						
Relevant Strategic Pr	iority							
Outstanding Care ⊠	Healthy Co	ommunities 🗵	Great Place to	o Work 🗵	Net Zero ⊠			
Relevant objective								
<ul> <li>☑ Improve waiting times in</li> <li>☑ Improve elective waiting</li> <li>☑ Improve safety through of accreditation</li> </ul>	living in most nities the best od pressure	⊠ Zero toler	ance to bullying					
Patient Safety	Implications / Impact Patient Safety				Aspects of patient safety were considered at relevant points in the meeting			
Risk: link to Board Assur Register	ance Frame	work (BAF)/Risk	Any relevant risk was highlighted within the reports and during the discussion					
Financial			Where finance had an impact, it was highlighted and discussed as appropriate					
Compliance			Compliance with legislation and CQC standards were highlighted when required or relevant					
Partnership: consultati	n/a							
Equality			Any equality issues were highlighted and discussed as required.					
Quality Impact Assessment [QIA] completion required?			No					





**Meeting:** Trust Board Meeting in Public

Date: 27 November 2024

Agenda item	BHPL Annual Accounts 2023/24
Board Lead	Jon Evans, Chief Finance Officer
Author	Wayne Preston, Commercial Director
Appendices	BHPL Annual Accounts 2023/24
Purpose	Assurance
Previously considered	BHPL Board have approved the accounts.

### **Executive summary**

The Trust's wholly owned subsidiary Company, Buckinghamshire Healthcare Projects Ltd (BHPL) has operated as a trading company since 2018 and is now well-established, providing outpatient pharmacy services in the main hospital sites at the Trust as well as a café and salon in the National Spinal Injuries Unit. The attached report comprises its end of year audited accounts, where the audit opinion is that the financial statements:

- give a true and fair view of the state of the company's affairs as of 31 March 2024, for the 2023/24 financial year.
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice.
- have been prepared in accordance with the requirements of the Companies Act 2006.

The key 2023/24 highlights were:

- The company has grown its annual turnover by 19% to £9.976m, it now employs forty people and delivered a gross profit of £1.8m, up 17% on last year.
- Debtors reduced by 25% to £295k.
- During the year, the Outpatient Pharmacy service delivered over 125,000 prescriptions.
- The company made a £66k loss in year but this included costs of £246k establishing capacity in readiness to take on board the operating of Private Patient Services.

BHPL has maintained its Social Enterprise status and continues to adopt the principles of The Blueprint for Better Business.

There was one action required by the auditors:

- Costs incurred by BHPL driving benefit solely for BHT should be recharged.

The value was below materiality levels, £44k plus vat, and as such the Accounts for 2023/24 have not been amended and the recharge will be enacted in 2024/25.

A verbal update of the discussions held at Finance & Business Performance Committee on 26 November 2024 will be provided to Trust Board.

Decision	The Committee is requested to note the Accounts as presented.						
Relevant strategic	evant strategic priority						
Outstanding Care ⊠	Healthy Communities	Great Place to Work ⊠	Net Zero □				
Relevant objective							

<ul><li>☑ Improve waiting times in ED.</li><li>☑ Improve elective waiting times.</li><li>☐ Improve safety through clinical accreditation</li></ul>	deprive start in	patient blood pressure	☐ Zero tolerance to bullying		
Implications / Impact	<u> </u>				
Patient Safety		BHPL adhere to all safety procedures where patient	•		
Risk: link to Board Assurance Frame (BAF) and local or Corporate Risk Re	-	Principal Risk 2: Failure to financial plan  No specific risk identified	in CRR.		
Financial		to BHT its parent compan	PL aims to deliver direct financial benefit back BHT its parent company.		
Compliance Select an item. Good Governance		Provide Committee with a governed.	ssurance BHPL is well		
Partnership: consultation / communication		BHPL works in partnershi	p with BHT.		
Equality		BHPL is committed to fair treatment of all patients, service users, visitors, and staff, regardless of age, colour, disability, ethnic gender, nationality, race, religion or belief, sexual orientation, or any other personal characteristics.			
Quality Impact Assessment [QIA] completion required?		No.			

# REPORT OF THE DIRECTORS AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

FOR

**BUCKINGHAMSHIRE HEALTHCARE PROJECTS LTD** 

# CONTENTS OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

	F	Page	9
Company Information		1	
Report of the Directors	2	to	3
Report of the Independent Auditors	4	to	7
Income Statement		8	
Balance Sheet		9	
Notes to the Financial Statements	10	to	13
Trading and Profit and Loss Account		14	

# COMPANY INFORMATION FOR THE YEAR ENDED 31 MARCH 2024

DIRECTORS: Ms K H A Archer

 $\mathsf{Ms} \; \mathsf{E} \; \mathsf{E} \; \mathsf{L} \; \mathsf{Siew}$ 

**REGISTERED OFFICE:** Trust Offices (Level 2)

Amersham Hospital Whielden Street Amersham Buckinghamshire

HP7 0JD

**REGISTERED NUMBER:** 10700085 (England and Wales)

AUDITORS: Seymour Taylor Limited, Statutory Auditor

First Floor North 40 Oxford Road High Wycombe Buckinghamshire

HP11 ŽEE

# REPORT OF THE DIRECTORS FOR THE YEAR ENDED 31 MARCH 2024

The directors present their report with the financial statements of the company for the year ended 31 March 2024.

#### **DIRECTORS**

The directors who have held office during the period from 1 April 2023 to the date of this report are as follows:

Mrs R K Devonshire - resigned 19 February 2024 Mrs A M Williams - resigned 31 January 2024 Mr M Taylor - appointed 31 January 2024 Ms K H A Archer - appointed 31 January 2024

Ms E E L Siew was appointed as a director after 31 March 2024 but prior to the date of this report.

Mr M Taylor ceased to be a director after 31 March 2024 but prior to the date of this report.

### STATEMENT OF DIRECTORS' RESPONSIBILITIES

The directors are responsible for preparing the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

#### STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS

So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that she ought to have taken as a director in order to make herself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

#### **AUDITORS**

The auditors, Seymour Taylor Limited, will be re-appointed in accordance with section 487(2) of the Companies Act 2006.

# REPORT OF THE DIRECTORS FOR THE YEAR ENDED 31 MARCH 2024

This report has been prepar relating to small companies.	red in accordance	e with th	e provisions	of Part	15 of	the	Companies	Act	2006
ON BEHALF OF THE BOAR	D:								
Ms K H A Archer - Director									
Date:									

### **Opinion**

We have audited the financial statements of Buckinghamshire Healthcare Projects Ltd (the 'company') for the year ended 31 March 2024 which comprise the Income Statement, Balance Sheet and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the company's affairs as at 31 March 2024 and of its loss for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice;
   and
- have been prepared in accordance with the requirements of the Companies Act 2006.

### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

#### Other information

The directors are responsible for the other information. The other information comprises the information in the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Report of the Directors has been prepared in accordance with applicable legal requirements.

### Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the directors were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemption from the requirement to prepare a Strategic Report or in preparing the Report of the Directors.

### Responsibilities of directors

As explained more fully in the Statement of Directors' Responsibilities set out on page two, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

#### Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Identifying and assessing potential risks related to irregularities

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, we considered the following:

- the nature of the industry and sector, control environment and business performance;
- results of our enquiries of management about their own identification and assessment of the risks of irregularities;
- any matters we identified in respect of the Company's documentation of their policies and procedures relating to:
- identifying, evaluating and complying with laws and regulations and whether they were aware of any instances of noncompliance;
- detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected or alleged fraud;
- the internal controls established to mitigate risks of fraud or non-compliance with laws and regulations;
- the matters discussed among the audit engagement team and involving relevant internal specialists, including tax regarding how and where fraud might occur in the financial statements and any potential indicators of fraud.

As a result of these procedures, we considered the opportunities and incentives that may exist within the organisation for fraud. In common with all audits under ISAs (UK), we are also required to perform specific procedures to respond to the risk of management override.

We also obtained an understanding of the legal and regulatory frameworks that the Company operates in, focusing on provisions of those laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements. The key laws and regulations we considered in this context included the UK Companies Act and local tax legislation.

In addition, we considered provisions of other laws and regulations that do not have a direct effect on the financial statements but compliance with which may be fundamental to the Company's ability to operate or to avoid a material penalty.

#### Audit response to risks identified

As a result of performing the above, we identified revenue deferrals as a key audit matter related to the potential risk of fraud. The key audit matters section of our report explains the matter in more detail and also describes the specific procedures we performed in response to that key audit matter. Our procedures to respond to risks identified included the following:

- reviewing the financial statement disclosures and testing to supporting documentation to assess compliance with provisions of relevant laws and regulations described as having a direct effect on the financial statements;
- enquiring of management concerning actual and potential litigation and claims;
- performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;
- obtained an understanding of provisions and held discussions with management to understand the basis of recognition or non-recognition of tax provisions; and
- in addressing the risk of fraud through management override of controls, testing the appropriateness of journal entries and other adjustments; assessing whether the judgements made in making accounting estimates are indicative of a potential bias; and evaluating the business rationale of any significant transactions that are unusual or outside the normal course of business.

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members including internal specialists and significant component audit teams, and remained alert to any indications of fraud or noncompliance with laws and regulations throughout the audit.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

### Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Elizabeth Horton ACA FCCA (Senior Statutory Auditor) for and on behalf of Seymour Taylor Limited, Statutory Auditor First Floor North 40 Oxford Road High Wycombe Buckinghamshire HP11 2EE

Date: .....

# INCOME STATEMENT FOR THE YEAR ENDED 31 MARCH 2024

Notes	31.3.24 £	31.3.23 £
TURNOVER	9,975,913	8,400,455
Cost of sales	8,149,212	6,844,387
GROSS PROFIT	1,826,701	1,556,068
Administrative expenses	1,943,984	1,527,103
OPERATING (LOSS)/PROFIT 4	(117,283)	28,965
Interest receivable and similar income	29,850	14,717
	(87,433)	43,682
Interest payable and similar expenses		152
(LOSS)/PROFIT BEFORE TAXATION	(87,433)	43,530
Tax on (loss)/profit	(21,048)	8,271
(LOSS)/PROFIT FOR THE FINANCIAL YEAR	(66,385)	35,259

The notes on pages 10 to 13 form part of these financial statements

# **BUCKINGHAMSHIRE HEALTHCARE PROJECTS LTD (REGISTERED NUMBER: 10700085)**

# BALANCE SHEET 31 MARCH 2024

Ms K H A Archer - Director

		31.3.	24	31.3.2	23
	Notes	£	£	£	£
FIXED ASSETS Tangible assets	5		117,863		91,566
CURRENT ASSETS					
Stocks		500,409		544,791	
Debtors	6	295,544		403,535	
Cash at bank		262,539		687,213	
		1,058,492		1,635,539	
CREDITORS					
Amounts falling due within one year	7	750,246		1,234,611	
NET CURRENT ASSETS			308,246		400,928
TOTAL ASSETS LESS CURRENT					
LIABILITIES			426,109		492,494
CAPITAL AND RESERVES					
Called up share capital	9		1		1
Retained earnings	-		426,108		492,493
SHAREHOLDERS' FUNDS			426,109		492,494

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

	statements		•		Directors	and	authorised	for	issue	on

The notes on pages 10 to 13 form part of these financial statements

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

#### 1. STATUTORY INFORMATION

Buckinghamshire Healthcare Projects Limited is a private company limited by shares and incorporated in England and Wales. The address of the company's registered office and principal place of business is Trust Office (Level 2), Amersham Hospital, Whieldon Street, Amersham, Buckinghamshire, HP7 0JD. The registered number is 10700085.

The principal activity of the company in the period under review was that of provision of pharmacies in Buckinghamshire hospitals.

The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

### 2. **ACCOUNTING POLICIES**

#### Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

#### Significant judgements and estimates

The preparation of the financial statements requires management to make estimates and assumptions that affect the reported amounts of revenue, expenses, assets and liabilities, and the disclosure of contingent liabilities at the date of the financial statements. If in the future such estimates and assumptions, which are based on the management's best judgment at the date of the financial statements, deviate from the actual circumstances, the original estimates and assumptions will be modified as appropriate in the year in which the circumstances change.

#### **Turnover**

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

### **Tangible fixed assets**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery etc - s

 straight line - 20%, straight line - 10%, straight line - 5% and straight line - 2%

All tangible fixed assets are stated at cost less accumulated depreciation and accumulated impairment losses. Such costs include costs directly attributable to making the asset capable of operating as intended.

#### **Stocks**

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

#### **Financial instruments**

The company has applied the provisions of Section 11 "Basic Financial Instruments" and Section 12 "Other Financial Instrument Issues" of FRS 102 to its financial statements.

Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

# NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2024

### 2. ACCOUNTING POLICIES - continued

#### **Taxation**

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

#### **Deferred tax**

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

### Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

#### **Leasing commitments**

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

#### 3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 37 (2023 - 33).

### 4. OPERATING (LOSS)/PROFIT

The operating loss (2023 - operating profit) is stated after charging:

	31.3.24	31.3.23
	£	£
Depreciation - owned assets	26,857	21,581

# NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2024

5.	TANGIBLE FIXED ASSETS		
			Plant and machinery etc £
	COST At 1 April 2023 Additions		193,533 53,154
	At 31 March 2024		246,687
	DEPRECIATION At 1 April 2023 Charge for year		101,967 26,857
	At 31 March 2024		128,824
	NET BOOK VALUE At 31 March 2024		117,863
	At 31 March 2023		91,566
6.	DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR	31.3.24 £	31.3.23 £
	Trade debtors Other debtors	1,006 294,538	2,986 400,549
		295,544	403,535
7.	CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR		
		31.3.24 £	31.3.23 £
	Trade creditors Taxation and social security Other creditors	652,284 34,198 63,764	619,912 37,561 577,138
		750,246	1,234,611
8.	LEASING AGREEMENTS		
	Minimum lease payments under non-cancellable operating leases fall due	as follows: 31.3.24 £	31.3.23 £
	Within one year Between one and five years	97,845 257,359	91,138 129,419
		355,204	220,557

# NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2024

### 9. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

### 10. PENSION COMMITMENTS

The company operates a defined contribution scheme with contributions paid in the accounting period charged to the profit and loss account. The pension cost charge represents contributions payable by the company to the fund and amounted to £72,943 (2023: £79,095).

### 11. RELATED PARTY DISCLOSURES

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

# 12. ULTIMATE CONTROLLING PARTY

The ultimate controlling party is Buckinghamshire Healthcare NHS Trust.

# TRADING AND PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 31 MARCH 2024

	31.3.24		31.3.23	
	£	£	£	£
Turnover		9,975,913		8,400,455
Cost of sales		8,149,212		6,844,387
GROSS PROFIT		1,826,701		1,556,068
Other income Bank account interest		20.050		44747
Dank account interest		29,850		14,717
		1,856,551		1,570,785
Expenditure Rates and water Insurance Pharmacy cover Directors' salaries Wages Social security Pensions Locums Printing, post and stationery Advertising Travel and subsistence Repairs and renewals Finance services Directors and company secretary Human resources services Subscriptions Sundry expenses Premises Info Gov Consultancy services Research and development costs Training Auditors' remuneration Depreciation of tangible fixed assets Profit/loss on sale of tangible fixed assets	8,965 13,876 54,588 37,700 1,253,248 123,381 72,943 45,408 5,962 23,183 6,604 10,093 27,840  8,911 6,318 41,535 11,245 116,992 3,340 18,201 4,172 2,164 12,048 26,857	1,935,574	12,818 53,000 5,940 936,611 84,009 79,095 48,505 6,162 4,619 12,931 27,029 8,650 8,406 28,460 35,362 104,693 3,244 17,500 2,626 7,154 11,555 21,581	1,520,247
		(79,023)		50,538
Finance costs Bank charges Bank interest	8,410 	8,410	6,856 152	7,008
NET (LOSS)/PROFIT		(87,433)		43,530

This page does not form part of the statutory financial statements

NOTES WHOLLY REPLACED
AND/OR ACCOUNTING POLICIES TOTALLY IGNORED
AND/OR ACCOUNTING POLICIES WITH TEXT REPLACED
BY USER'S CHOICE ON CLIENT SCREEN ENTRIES
FOR THE YEAR ENDED 31 MARCH 2024

The following note has been REPLACED completely by user entries.  STATUTORY INFORMATION
None of the standard accounting policies has been ignored.
None of the standard accounting policies has been replaced.
PLEASE CHECK THAT THIS CHOICE IS CORRECT - all changes that would automatically be made to notes generated by IRIS as a result of posting amendments etc WILL NOT BE AMENDED where REPLACEMENT notes have been selected.





Meeting: Trust Board Meeting in Public

# **27 November 2024**

Agenda item	Use of the Trust Seal	
Board Lead	Neil Macdonald, Chief Executive Officer	
Type name of Author	Elisabeth Jones, Senior Board Administrator	
Attachments	None	
Purpose	Information	
Previously considered	None	
Executive Summary		
TI D 1: 1 1: 1 1: 1 1: 1 1: 1 1: 1 1: 1 1		

The Board is asked to note the use of the Trust seal in accordance with Standing Orders (Sealing of Documents)

(ocaling of bootiments)					
Decision	The Bo	pard is asked to	note the informati	on within	the report.
Relevant Strategic P	riority				
Outstanding Care 🗵   I	Healthy Co	ommunities 🗵	Great Place to Work ⊠		Net Zero □
Relevant objective					
☐ Improve waiting times in	n ED	☐ Give children	•	☐ Zero to	olerance to
☐ Improve elective waiting times		deprived communities the best start in life		bullying	
☐ Improve safety through	clinical	☐ Outpatient blood pressure			
accreditation		checks			
Implications / Impac	t				
Patient Safety		The use of the Trust Seal does not			
-		have an impact on patient safety			
Risk: link to Board Assurance Framework (BAF)/Risk Register		There are no relevant risks relating to the Trust Seal on the CRR or BAF			
Financial		The Trust Seal is used in accordance			
		with the Trust Standing Financial Instructions and Standing Orders			
Camplianas Caad Cayamana					
Compliance Good Governance		Meets the requirements of the Trust Standing Orders			
Partnership: consultation / communication		Partnership working is undertaken in			
Equality		the drawing up of the documents  The use of the Trust Seal does not			
Equality		affect Equality			
Quality Impact Assessment [QIA] completion required?		Not required			

# 1 Introduction

There have been 8 occasions since the last report to the Trust Board (November 2023) which have required the use of the official Trust seal:

Date of Sealing	Details
05 December 2023	Purchase of lease demise from L&Q for accommodation at Wycombe and the Trust.
	Value of £2,075,000.
	Signed by Chief Finance Officer and Chief People Officer
14 December 2023	Lease for Mandeville Medical company of Building 77 on the Stoke Mandeville site.
	£59,901 /yr.
	Signed by Chief Medical Officer and Chief Operating Officer
20 March 2024	Two-year lease of Harrington House
	£556k
	Signed by Chief Estates and Facilities Officer and Chief Finance Officer
09 April 2024	Deed of Assignment of Arrears related to the Trust purchase, from London and Quadrant Housing Trust (L&Q), of the lease associated with the key worker housing on the Wycombe Hospital site.
	£7,452.
	Signed by Chief Estates and Facilities Officer and Chief Finance Officer
21 May 2024	Deed of Covenant between the Trust and L&G owners of Asda site.
	No financial value.
	Signed by Chief Operating Officer and Chief Estates and Facilities Officer
30 May 2024	Unilateral Undertaking (UU) for the agreement for the planning permission to be issued to the Trust for the new capital project.
	£5350 for the Travel Plan referred to in the UU. £252 for the monitoring of the s106 agreement referred to in the UU.
	Signed by Chief Operating Officer and Chief Estates and Facilities Officer

23 August 2024	Lease of adjoining Forest School - Child Base Partnership Ltd.
	£13,500 per year with 2.5% fixed inflationary charge per year
	Signed by Chief Estates and Facilities Officer and Chief Digital & Transformation Officer
09 October 2024	Lease between the Trust and Alexandra House (former Staples building)
	£150k
	Signed by Chief Finance Officer and Chief Digital and Transformation Officer

In accordance with the Trusts Standing Orders:

# 8.5.2. Sealing of Documents

Where it is necessary that a document shall be sealed, the seal shall be affixed in the presence of two senior managers duly authorised by the Chief Executive, and not also from the originating department, and shall be attested by them.

# 2 Action required from Trust Board

The Board is asked to note the use of the Trust seal in accordance with Standing Orders (Sealing of Documents).





### Acronvm 'Buster'

- A&E Accident and Emergency
- · AD Associate Director
- ADT Admission, Discharge and Transfer
- AfC Agenda for Change
- AGM Annual General Meeting
- AHP Allied Health Professional
- AIS Accessible Information Standard
- AKI Acute Kidney Injury
- AMR Antimicrobial Resistance
- ANP Advanced Nurse Practitioner
- APC Acute Provider Collaborative

# B

- BBE Bare Below Elbow
- BHT Buckinghamshire Healthcare Trust
- BME Black and Minority Ethnic
- BMA British Medical Association
- BMI Body Mass Index
- BOB Buckinghamshire, Oxfordshire & Berkshire West
- BPPC Better Payment Practice Code

# C

- CAMHS Child and Adolescent Mental Health Services
- CAS Central Alert System
- CCG Clinical Commissioning Group
- CCU Coronary Care Unit
- Cdif / C.Diff Clostridium Difficile
- CDU Clinical Decision Unit
- CEA Clinical Excellence Awards
- CEO Chief Executive Officer
- · CHD Coronary Heart Disease
- CIO Chief Information Officer
- · CIP Cost Improvement Plan
- CQC Care Quality Commission
- CQUIN Commissioning for Quality and Innovation
- CRL Capital Resource Limit
- CSRU Cardiac & Stroke Receiving Unit
- CSU Commissioning Support Unit
- CT Computerised Tomography
- CTG Cardiotocography

# D

- DBS Disclosure Barring Service
- DGH District General Hospital
- DH / DoH Department of Health
- DIPC Director of Infection Prevention and Control
- DNA Did Not Attend
- DNACPR Do Not Attempt Cardiopulmonary Resuscitation
- DNAR Do Not Attempt Resuscitation
- DNR Do Not Resuscitate
- DoLS Deprivation of Liberty Safeguards
- DPA Data Protection Act
- DSU Day Surgery Unit
- DVT Deep Vein Thrombosis

# E

- ED&I Equality, Diversity & Inclusion
- EBITDA Earnings Before Interest, Taxes, Depreciation and Amortization
- ECG Electrocardiogram
- ED Emergency Department
- EDD Estimated Date of Discharge
- EQIA Equality & Quality Impact Assessment
- EIS Elective Incentive Scheme
- EMRU Emergency Medicine Receiving Unit
- ENT Ear, Nose and Throat
- · EOLC End of Life Care
- EPR Electronic Patient Record
- EPRR Emergency Preparedness, Resilience and Response
- ERF Elective Recovery Fund
- ESD Early Supported Discharge
- ESR Electronic Staff Record

# F

- FBC Full Business Case
- · FFT Friends and Family Test
- FOI Freedom of Information
- FTE Full Time Equivalent

# G

- · GI Gastrointestinal
- GMC General Medical Council
- GP General Practitioner
- GRE Glycopeptide Resistant Enterococci

# H

- HAI Hospital Acquired Infection
- HASU Hyper Acute Stroke Unit
- HCA Health Care Assistant
- HCAI Healthcare-Associated Infection
- HDU High Dependency Unit

- HEE Health Education England
- HETV Health Education Thames Valley
- HMRC Her Majesty's Revenue and Customs
- HSE Health and Safety Executive
- HSLI Health System Led Investment
- HSMR Hospital-level Standardised Mortality Ratio
- HSW Healthcare Support Worker
- · HWB Health and Wellbeing Board



- ICS Integrated Care System
- ICB Integrated Care Board



- I&E Income and Expenditure
- IC Information Commissioner
- ICP Integrated Care Pathway
- ICU Intensive Care Unit
- IG Information Governance
- IGT / IGTK Information Governance Toolkit
- IM&T Information Management and Technology
- IPR Integrated Performance Report
- ITU Intensive Therapy Unit / Critical Care Unit
- IV Intravenous



JAG - Joint Advisory Group

# K

KPI - Key Performance Indicator



- LA Local Authority
- LCFS Local Counter Fraud Specialist
- LD Learning Disability
- LHRP Local Health Resilience Partnership
- LiA Listening into Action
- LOS / LoS Length of Stay
- LUCADA Lung Cancer Audit Data

# M

- M&M Morbidity and Mortality
- MDT Multi-Disciplinary Team
- MIU Minor Injuries Unit
- MfOP Medicine for Older People

- MOfD Medically Optimised for Discharge
- MRI Magnetic Resonance Imaging
- MRSA Meticillin-Resistant Staphylococcus Aureus

# R

- NBOCAP National Bowel Cancer Audit Programme
- NCASP National Clinical Audit Support Programme
- NED Non-Executive Director
- NHS National Health Service
- NHSE National Health Service England
- NHSLA NHS Litigation Authority
- NICE National Institute for Health and Care Excellence
- NICU Neonatal Intensive Care Unit
- NMC Nursing and Midwifery Council
- NNU Neonatal Unit
- NOGCA National Oesophago-Gastric Cancer Audit
- NRLS National Reporting and Learning System / Service



- · O&G Obstetrics and Gynaecology
- · OBC Outline Business Case
- ODP Operating Department Practitioner
- OHD Occupational Health Department
- · OOH Out of Hours
- OP Outpatient
- OPD Outpatient Department
- OPEL Operational Pressure Escalation Level (1-4)
- OT Occupational Therapist/Therapy
- · OUH Oxford University Hospital

# P

- PACS Picture Archiving and Communications System / Primary and Acute Care System
- · PALS Patient Advice and Liaison Service
- PAS Patient Administration System
- · PBR Payment by Results
- PBR Excluded Items not covered under the PBR tariff
- PDC Public Dividend Capital
- · PDD Predicted Date of Discharge
- PE Pulmonary Embolism
- PFI Private Finance Initiative
- PHE Public Health England
- · PICC Peripherally Inserted Central Catheters
- PID Patient / Person Identifiable Data
- PID Project Initiation Document
- PLACE Patient-Led Assessments of the Care Environment
- PMO Programme Management Office
- PPE Personal Protective Equipment
- PP Private Patients
- PPI Patient and Public Involvement
- PSED Public Sector Equality Duty
- PSIRF Patient Safety Incident Response Framework

# Q

- QA Quality Assurance
- QI Quality Indicator
- QIP Quality Improvement Plan
- QIPP Quality, Innovation, Productivity and Prevention
- QIA Quality Impact Assessment
- QOF Quality and Outcomes Framework

# R

- RAG Red Amber Green
- RCA Root Cause Analysis
- RCN Royal College of Nursing
- RCP Royal College of Physicians
- RCS Royal College of Surgeons
- RIDDOR Reporting of Injuries, Diseases and Dangerous Occurrences Regulations
- RSV Respiratory Syncytial Virus
- · RTT Referral to Treatment

# S

- · SAU Surgical Assessment Unit
- SCAS South Central Ambulance Service
- SEND Special Educational Needs & Disability
- SHMI Summary Hospital-level Mortality Indicator
- · SI Serious Incident
- SIRO Senior Information Risk Owner
- SID Senior Independent Director
- SLA Service Level Agreement
- SLR Service-Line Reporting
- SLT / SaLT Speech and Language Therapy
- SMR Standardised Mortality Ratio
- SoS Secretary of State
- SSI(S) Surgical Site Infection (Surveillance)
- SNAP Sentinel Stroke National Audit Programme
- STF Strategic Transformation Fund
- STP Sustainability and Transformation Plan
- SUI Serious Untoward Incident

# T

- TIA Transient Ischaemic Attack
- TNA Training Needs Analysis
- TPN Total Parenteral Nutrition
- TTA To Take Away
- TTO To Take Out
- TUPE Transfer of Undertakings (Protection of Employment) Regulations 1981

#### U

- UGI Upper Gastrointestinal
- UTI Urinary Tract Infection



- VfM Value for Money
  VSM Very Senior Manager
  VTE Venous Thromboembolism



- WHO World Health OrganizationWTE Whole Time Equivalent



• YTD - Year to Date